Elite 50% OFF Act now – get top investing tools Register Now!

Immuneering Corporation

Contributing Author

Recent Articles by Immuneering Corporation

Nov-12	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates IMRX GlobeNewswire
Nov-04	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 IMRX GlobeNewswire
Sep-26	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 IMRX GlobeNewswire
Sep-25	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi IMRX GlobeNewswire
Sep-24	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi IMRX GlobeNewswire
Sep-24	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP IMRX GlobeNewswire
Sep-16	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board IMRX GlobeNewswire
Sep-10	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 IMRX GlobeNewswire
Aug-26	Immuneering Announces Closing of $25 Million Private Placement IMRX GlobeNewswire
Aug-25	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib IMRX GlobeNewswire
Aug-21	Immuneering Announces $25 Million Private Placement IMRX GlobeNewswire
Aug-13	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates IMRX GlobeNewswire
Jul-09	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib IMRX GlobeNewswire
Jun-17	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients IMRX GlobeNewswire
Jun-16	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 IMRX GlobeNewswire
May-29	Immuneering to Present at the Jefferies Global Healthcare Conference IMRX GlobeNewswire
May-05	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates IMRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.